Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 102

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Vesugen RESEARCH METHODS The patients’ complaints were assessed and compared, a general clinical examination of blood and urine was carried out alongside a biochemical study of blood using the «REFLOTRON» device (Boehringer Mannheim, Germany). A blood coagulogram and tourniquet Hesse testing were carried out to assess homeostasis. RESEARCH RESULTS The use of VESUGEN® in patients with arterial atherosclerosis contributed to the improvement of general health, normalization of sleep, especially in patients with cerebrovascular disorders. Patients with ischemic heart disease noted a decrease in cardiac arrhythmias manifestations and angina attacks. Patients with essential hypertension associated the normalization of blood pressure with the use of VESUGEN® in combination with antihypertensive drugs since it was possible to achieve long-term remission between hypertensive crises with a lower dose of conventional antihypertensive drugs. As we can see from table 2, the use of VESUGEN® contributed to a significant decrease in the level of total cholesterol in the blood. There was also a tendency to decrease the content of very-low- density lipoproteins, which are the most atherogenic. Table 2 Influence of VESUGEN®on lipid metabolism indicators in patients with arterial atherosclerosisIndicator Before After treatment using After treatment using treatment general purpose drugs Vesugen® General cholesterol, (mmol/l) 8,2±0,3 7,0±0,2* 6,4±0,3* Very little density lipoproteins, 1,23±0,05 1,08±0,04 0,96±0,05 (mmol/l) Triglycerides, (mmol/l) 4,5±0,2 4,2±0,7 4,1±0,2 *P<0,05–reliable in comparison with the indicator before treatment. Thus, the results of this study indicate the therapeutic efficacy of VESUGEN® and the advisability of its use in the complex treatment of atherosclerosis and vascular pathology. VESUGEN® administration has not resulted in any side effects, complications, contraindications, or drug dependence. VESUGEN® is convenient for administration in hospitals, outpatient, and home use. VESUGEN® can be used for therapeutic and prophylactic purposes as a biologically active food supplement as part of the complex therapy of vascular atherosclerosis and improve microcirculation in various tissues in combination with any means of symptomatic and pathogenetic treatment. CONCLUSION The biologically active food supplement VESUGEN® has a regulatory effect on metabolism in the vascular wall cells, contributing to the regulation of lipid metabolism and improving the state of the vascular wall. VESUGEN® is well tolerated at oral administration, has no side effects, has no contraindications, and can be used as part of the complex treatment and prevention of vascular diseases of various origins. VESUGEN® is recommended to improve the functions of the vascular wall in cases of atherosclerosis, microcirculation disorders in organs and tissues in various diseases, and the influence of various extreme factors on the body. It is also recommended for the elderly to maintain vascular system function. Recommended dosages: orally 10-15 minutes before meals, 1-3 tablets or capsules 2-3 times a day for 10-20 days. It is advisable to carry out repeated courses of treatment every 3-6 months.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.